FDA approves Lilly's once-weekly basal insulin Onswik for type 2 diabetes

The U.S. Food and Drug Administration has approved Eli Lilly's Onswik, a once-weekly basal insulin for adults with type 2 diabetes. The treatment offers patients an alternative to daily long-acting insulin injections for managing blood sugar.